Cargando…
Treatment-refractory anxiety; definition, risk factors, and treatment challenges
A sizable proportion of psychiatric patients will seek clinical evaluation and treatment for anxiety symptoms reportedly refractory to treatment. This apparent lack of response is either due to “pseudo-resistance” (a failure to have received and adhered to a recognized and effective treatment or tre...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Les Laboratoires Servier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518702/ https://www.ncbi.nlm.nih.gov/pubmed/26246793 |
_version_ | 1782383401268936704 |
---|---|
author | Roy-Byrne, Peter |
author_facet | Roy-Byrne, Peter |
author_sort | Roy-Byrne, Peter |
collection | PubMed |
description | A sizable proportion of psychiatric patients will seek clinical evaluation and treatment for anxiety symptoms reportedly refractory to treatment. This apparent lack of response is either due to “pseudo-resistance” (a failure to have received and adhered to a recognized and effective treatment or treatments for their condition) or to true “treatment resistance.” Pseudo-resistance can be due to clinician errors in selecting and delivering an appropriate treatment effectively, or to patient nonadherence to a course of treatment. True treatment resistance can be due to unrecognized exogenous anxiogenic factors (eg, caffeine overuse, sleep deprivation, use of alcohol or marijuana) or an incorrect diagnosis (eg, atypical bipolar illness, occult substance abuse, attention deficit-hyperactivity disorder). Once the above factors are eliminated, treatment should focus on combining effective medications and cognitive behavioral therapy, combining several medications (augmentation), or employing novel medications or psychotherapies not typically indicated as first-line evidence-based anxiety treatments. |
format | Online Article Text |
id | pubmed-4518702 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Les Laboratoires Servier |
record_format | MEDLINE/PubMed |
spelling | pubmed-45187022015-08-05 Treatment-refractory anxiety; definition, risk factors, and treatment challenges Roy-Byrne, Peter Dialogues Clin Neurosci Clinical Research A sizable proportion of psychiatric patients will seek clinical evaluation and treatment for anxiety symptoms reportedly refractory to treatment. This apparent lack of response is either due to “pseudo-resistance” (a failure to have received and adhered to a recognized and effective treatment or treatments for their condition) or to true “treatment resistance.” Pseudo-resistance can be due to clinician errors in selecting and delivering an appropriate treatment effectively, or to patient nonadherence to a course of treatment. True treatment resistance can be due to unrecognized exogenous anxiogenic factors (eg, caffeine overuse, sleep deprivation, use of alcohol or marijuana) or an incorrect diagnosis (eg, atypical bipolar illness, occult substance abuse, attention deficit-hyperactivity disorder). Once the above factors are eliminated, treatment should focus on combining effective medications and cognitive behavioral therapy, combining several medications (augmentation), or employing novel medications or psychotherapies not typically indicated as first-line evidence-based anxiety treatments. Les Laboratoires Servier 2015-06 /pmc/articles/PMC4518702/ /pubmed/26246793 Text en Copyright: © 2015 Institut la Conférence Hippocrate - Servier Research http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Research Roy-Byrne, Peter Treatment-refractory anxiety; definition, risk factors, and treatment challenges |
title | Treatment-refractory anxiety; definition, risk factors, and treatment challenges |
title_full | Treatment-refractory anxiety; definition, risk factors, and treatment challenges |
title_fullStr | Treatment-refractory anxiety; definition, risk factors, and treatment challenges |
title_full_unstemmed | Treatment-refractory anxiety; definition, risk factors, and treatment challenges |
title_short | Treatment-refractory anxiety; definition, risk factors, and treatment challenges |
title_sort | treatment-refractory anxiety; definition, risk factors, and treatment challenges |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518702/ https://www.ncbi.nlm.nih.gov/pubmed/26246793 |
work_keys_str_mv | AT roybyrnepeter treatmentrefractoryanxietydefinitionriskfactorsandtreatmentchallenges |